Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for January 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Methotrexate Well Tolerated, Effective for Psoriasis in Chinese
THURSDAY, Jan. 31, 2019 (HealthDay News) — Methotrexate is well tolerated and effective for psoriasis in a Chinese population and is more effective for those without psoriatic arthritis, according to a study published online Jan. 30 in JAMA Dermatology.
Evidence Lacking for Benefit of Surgery for Vertebral Fractures
MONDAY, Jan. 28, 2019 (HealthDay News) — Surgical procedures do not appear to provide significant benefit for patients with vertebral fractures (VF), according to a second American Society for Bone and Mineral Research Task Force report published in the January issue of the Journal of Bone and Mineral Research.
Report IDs Areas Lacking Good Practice in Health Tech Assessment
FRIDAY, Jan. 25, 2019 (HealthDay News) — In a report published in the January issue of Value in Health, an ISPOR–The Professional Society for Health Economics and Outcomes Research working group indicates the lack of good practices in three areas of health technology assessment (HTA).
Heberden’s Nodes in Fingers Tied to Knee Osteoarthritis
TUESDAY, Jan. 22, 2019 (HealthDay News) — The presence of Heberden’s nodes (HNs) in finger joints may also indicate structural damage associated with knee osteoarthritis, according to a study published online Jan. 9 in Arthritis & Rheumatology.
Radiographic Knee Osteoarthritis Tied to Increased Risk for Death
FRIDAY, Jan. 18, 2019 (HealthDay News) — Radiographic knee osteoarthritis (RKOA) is associated with an increased risk for mortality from cardiovascular disease (CVD), diabetes, and renal diseases, but self-reported OA is not, according to a study published in the December issue of the International Journal of Epidemiology.
FDA Down to 5 Weeks of Funding to Review New Drug Applications
THURSDAY, Jan. 17, 2019 (HealthDay News) — Due to the federal government shutdown, the U.S. Food and Drug Administration has only about five weeks of funding left to review new drug applications, according to Commissioner Scott Gottlieb, M.D.
Hemochromatosis Mutation Linked to Other Morbidity
THURSDAY, Jan. 17, 2019 (HealthDay News) — HFE p.C282Y homozygosity, the most common gene mutation causing hereditary hemochromatosis (type 1), is associated with other morbidity in men and women, according to a study published online Jan. 16 in The BMJ.